Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium
|
|
- Hilary Sullivan
- 5 years ago
- Views:
Transcription
1
2 Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium
3 Disclosures Honoraria and research support: Daiichi-Sankyo, Boehringer Ingelheim, Bayer HealthCare, Pfizer, Sanofi, Ionis Pharmaceuticals, Leo-Pharma, Bristol-Myers Squibb
4 Case: Recurrent VTE 41-year-old man Proximal DVT 2 years ago; R/ VKA Recurrent distal DVT; R/ NOAC Thrombophilia (FVLeiden) and familial history of VTE Frequent long-haul flights
5 Case: Recurrent VTE Your choice? 1. Stop Anticoagulation 2. VKA 3. ASA 100mg 4. LMWH 5. NOAC treatment dose 6. NOAC prophylactic dose
6 Case: Recurrent VTE 41-year-old man Proximal DVT 2 years ago; R/ VKA Recurrent distal DVT; R/ NOAC Thrombophilia (FVLeiden) and familial history of VTE Frequent long-haul flights
7 Case: PE in a young woman 33-year-old woman Pulmonary Embolism (RVD+, probnp+) Pill (COC)
8 Case: PE in a young woman 33-year-old woman Pulmonary Embolism (RVD+, probnp+) Pill (COC) PT G20210A heterozygous
9 Case: PE in a young women 33-year-old woman Pulmonary Embolism (RVD+, probnp+) Pill (COC) PT G20210A heterozygous + strong familial history
10 Case: Recurrent VTE Your choice? 1. Stop Anticoagulation 2. VKA 3. ASA 100mg 4. LMWH 5. NOAC treatment dose 6. NOAC prophylactic dose
11 Case: PE in a young women 33-year-old woman Pulmonary Embolism (RVD+, probnp+) Pill (COC) Antiphospholipid syndrome (LA++, ACL++)
12 Case: Recurrent VTE Your choice? 1. Stop Anticoagulation 2. VKA 3. ASA 100mg 4. LMWH 5. NOAC treatment dose 6. NOAC prophylactic dose
13 Risk of recurrence after unprovoked VTE is high 0.20 Unprovoked Cumulative proportion Non-surgical triggers Surgery Baglin T et al, Lancet 2003;362: Time since event (months)
14 Duration of Anticoagulant Therapy for VTE Stop therapy 3 months Continue therapy Kearon C et al, Chest 2016;149:
15 Duration of Anticoagulant Therapy for VTE Stop therapy 3 months Continue therapy Continue anticoagulant therapy in based on the individualized assessment of risks & benefits Kearon C et al, Chest 2016;149:
16 Balancing the Risk of Recurrent VTE versus Bleeding is Critical for Deciding to Extend Treatment RECURRENCES WITHOUT ANTICOAGULATION BLEEDING UNDER ANTICOAGULATION PATIENT S and PHYSICIAN S PREFERENCE Haxaire C et al, PLoS One 2015;10:e
17 Balancing the Risk of Recurrent VTE versus Bleeding is Critical for Deciding to Extend Treatment RECURRENCES WITHOUT ANTICOAGULATION BLEEDING UNDER ANTICOAGULATION PATIENT S and PHYSICIAN S PREFERENCE EFFICACY/SAFETY/CONVENIENCE OAC Haxaire C et al, PLoS One 2015;10:e
18 18
19 What to consider when deciding to extend anticoagulation therapy? Cumulative proportions of recurrent thrombosis after cessation of anticoagulant therapy 1 * (N=558) Cumulative proportion of recurrent events Time since event (months) Unprovoked Provoked by Nonsurgical risk factors Provoked by Surgery Extended anticoagulation therapy 2 3 months treatment duration 2 *Patients with malignant disease and antiphospholipid syndrome were excluded from the study. 1. Baglin T et al, Lancet 2003;362: Kearon C et al, Chest 2016;149:
20 Risk Factors for Recurrent VTE Recurrent VTE Unprovoked VTE VTE with Risk Factors: Major Transient Risk Factor Minor Transient Risk Factor Minor Persistent Risk Factor Major Persistent Risk Factor Kearon C et al, Chest 2016;149:
21 Assessing Recurrence Risk: Primary Estimators Primary estimator Surgical provoking risk factor: 1% in first year, 3% over 5 years Non-surgical provoking risk factor: 3% in first year, 15% over 5 years No provoking risk factor: 10% in first year, 30% over 5 years Persistent or progressive risk (e.g. cancer) Kearon C et al, Blood 2014;123:
22 Assessing Recurrence Risk: Secondary Estimators Secondary estimators Isolated distal DVT (50% lower than proximal DVT) Previous VTE (50% higher than first event) Secondary estimators after unprovoked event Male sex (1.5 2-fold increase) Positive D-Dimer 1 month after stopping ( fold higher) Kearon C et al, Blood 2014;123:
23 Risk Stratification in VTE Laboratory methods D-Dimer assay 5 Thrombin generation 6 Stratification methods Guidelines 4 1. Montagnana M et al, J Thromb Thrombolysis 2010;29:489-96; 2. Connolly GC et al, Best Pract Res Clin Haematol 2009;22:35-47; 3. Jimenez D et al, JAMA 2010;170: ; 4. Konstantinides et al. Eur Heart J 2014; pii: ehu283;4; 5. Eichinger S et al, JAMA 2003;290: ; 6. Lutsey PL et al, J Thromb Haemost 2009 ;7:
24 2016 ACCP Guidelines for VTE Antithrombotic Therapy Initial anticoagulation Acute DVT or haemodynamically stable PE and no cancer PE with hypotension ACCP recommendation NOAC preferred to VKA LMWH/VKA preferred to LMWH alone Thrombolytic therapy (systemic rather than catheter-directed unless bleeding risk is high) Grade of recommendation 2B 2C 2B (2C) DVT or PE with cancer LMWH suggested over NOAC or VKA 2C Duration of anticoagulant therapy Proximal DVT or PE 3 months recommended over shorter duration 1B First proximal DVT or PE provoked by surgery 3 months 1B Unprovoked DVT or PE Extended therapy if bleeding risk is low/moderate 2B 3 months if bleeding risk is high 1B DVT or PE associated with active cancer Extended therapy recommended over 3 months therapy 1B (2B if high bleeding risk) Kearon C et al, Chest 2016;149:
25 Risk Factors for Bleeding
26 Risk Factors for Bleeding Risk Factors Age >65 y Age >75 y Previous bleeding Cancer Metastatic cancer Renal failure Liver failure Thrombocytopenia Previous stroke Diabetes Anaemia Antiplatelet therapy Poor anticoagulant control Comorbidity and reduced functional capacity Recent surgery Frequent falls Alcohol abuse Nonsteroidal anti-inflammatory drug Anticoagulation 0-3 months Categorization of Risk of Bleeding Estimated Absolute Risk of Major Bleeding Low Risk (0 RF) Moderat e Risk (1 RF) Baseline risk (%) Increased risk (%) Total risk (%) Anticoagulation > 3 months Baseline risk (%/y) Increased risk (%/y) Total risk (%/y) High Risk (2 RF) Kearon C et al, Chest 2016;149:
27 Patient s and Physician s Preference
28 Patient s and Physician s Preference
29 EINSTEIN CHOICE Evaluated Rivaroxaban Versus ASA for Extended Treatment of VTE Multicentre, randomized, double-blind, active-comparator, event-driven, superiority study Population: Patients with confirmed symptomatic PE/DVT who completed 6 12 months anticoagulation* N=3396 Day 1 R Rivaroxaban 20 mg od n=1121 Rivaroxaban 10 mg od n=1136 ASA 100 mg od n= month planned treatment duration 30-day follow-up *Completed 6 12 months anticoagulation at randomization with no interruption of anticoagulation >1 week Patients randomized after the requisite number of primary efficacy outcomes was reached were treated for 6 months Weitz JI et al, Thromb Hemost 2015;114: ; Weitz JI et al, N Engl J Med 2017:doi: /NEJMoa
30 Both Rivaroxaban Doses Provided Superior Reduction in Recurrent VTE Rates Compared with ASA 5 ASA 100 mg od Cumulative incidence (%) Rivaroxaban 20 mg od Rivaroxaban 10 mg od Rivaroxaban 20 mg od vs ASA 1.5% vs 4.4% HR=0.34 (95% CI ), p<0.001 Rivaroxaban 10 mg od vs ASA 1.2% vs 4.4% HR=0.26 (95% CI ), p< Days Intention-to-treat analysis Weitz JI et al, N Engl J Med 2017:doi: /NEJMoa
31 Rates of Major Bleeding Were 0.5% and Similar to ASA 5 Cumulative incidence (%) Rivaroxaban 10 mg od Rivaroxaban 20 mg od vs ASA 6/1107 (0.5%) vs 3/1131 (0.3%) HR=2.01 (95% CI ), p=0.32 Rivaroxaban 10 mg od vs ASA 5/1127 (0.4%) vs 3/1131 (0.3%) HR=1.64 (95% CI ), p=0.50 Rivaroxaban 20 mg od Days ASA 100 mg od Safety analysis. No events after Day 360 up to Day 480 Weitz JI et al, N Engl J Med 2017:doi: /NEJMoa
32 Bleeding Outcome Analyses ASA 100 mg od (n=1131) Rivaroxaban 10 mg od (n=1127) Rivaroxaban 20 mg od (n=1107) 4 3,3 Incidence (%) ,3 0,4 0,5 2,0 2,4 1, ,7 1,1 1,1 1,5 0 Major bleeding Major or CRNM bleeding CRNM bleeding Non-major bleeding associated with study drug interruption for more than 14 days Similar rates of bleeding were observed in the rivaroxaban and ASA treatment groups Safety analysis. All treatment comparisons p>0.05 Weitz JI et al, N Engl J Med 2017:doi: /NEJMoa
33 Apixaban for Secondary Prevention of VTE Non-fatal and fatal VTE Placebo Apixaban 2.5 mg BD Apixaban 5 mg BD Cumulative event rate (%) Months Agnelli G et al. N Engl J Med 2013; 368:
34 Major or Clinically Relevant Nonmajor Bleeding Cumulative event rate (%) Placebo Apixaban 2.5 mg Apixaban 5 mg Months Agnelli G et al. N Engl J Med 2013; 368:
35 Case: Unprovoked PE 69-year-old man CAD, PCI LAD ASA 100mg, Statin, ACE-I Presents with unprovoked PE Familial history of VTE Treatment with NOAC initiated 1. with or without ASA 100mg? 2. without ASA 100mg?
36 Case: Unprovoked PE 69-year-old man CAD, PCI LAD ASA 100mg, Statin, ACE-I Presents with unprovoked PE Familial history of VTE Continued OAC after 3 months?
37 Case: Unprovoked PE 69-year-old man CAD, PCI LAD ASA 100mg, Statin, ACE Presents with unprovoked PE Familial history of VTE Continued OAC after 3 months? 1. with or without ASA 100mg? 2. without ASA 100mg?
38 Case: Recurrent VTE 29-year-old man Freak of Mountain bike and Snowboard Recurrent PE Continued OAC after 3 months?
39 Case: Recurrent VTE 29-year-old man Freak of Mountain biking and Snowboard Recurrent PE Continued OAC after 3 months 1. OD NOAC evening intake prophylactic dose? 2. OD NOAC evening intake therapeutic dose? 3. BD NOAC with antidote?
40 Thank you
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular
More informationDirect oral anticoagulants to prevent VTE recurrence: full or reduced dosage? MA Sevestre CHU Amiens
Direct oral anticoagulants to prevent VTE recurrence: full or reduced dosage? MA Sevestre CHU Amiens Faculty disclosure Marie Antoinette Sevestre I disclose the following financial relationships: Paid
More informationSpontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren
Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Paul Kyrle Allgemeines Krankenhaus Wien Disclosures relevant for this presentation Consultancies, member of advisory boards, speaker
More informationThe clinical relevance of AMPLIFY programme
Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationVENOUS THROMBOEMBOLISM: DURATION OF TREATMENT
VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationNOAC s across indications
Sektion CAMPUS INNENSTADT Med. Klinik und Poliklinik IV NOAC s across indications Ulrich Hoffmann, M.D. Division of Vascular Medicine University Hospital Munich, Germany Disclosure Speaker name: Ulrich
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationOral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study.
Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study Comments Harald Darius, Berlin Disclosures for Harald Darius Research
More informationDuration of anticoagulation
Duration of anticoagulation P. Fontana Service d angiologie et d hémostase Hôpitaux Universitaires de Genève Pomeriggio formativo in coagulazione, Bellinzona, 19.10.2017 Conflict of interest AstraZeneca,
More informationA Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism
Cardiol Ther (2018) 7:1 13 https://doi.org/10.1007/s40119-018-0107-0 REVIEW A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism Andrew
More informationKeynote lecture: Oral anticoagulation and DVT
Keynote lecture: Oral anticoagulation and DVT What is the evidence? Is there a need to anticoagulate every lower leg DVT? Disclosure Speaker name:...sebastian Schellong... I have the following potential
More informationDuration of Therapy for Venous Thromboembolism
Duration of Therapy for Venous Thromboembolism Michael B Streiff, MD FACP Associate Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee
More informationΘεραπεία και Πρόληψη Θρομβώσεων και Πνευμονικών Εμβολών Τι μάθαμε το 2017; Τι περιμένουμε το 2018;
Θεραπεία και Πρόληψη Θρομβώσεων και Πνευμονικών Εμβολών Τι μάθαμε το 2017; Τι περιμένουμε το 2018; Stavros V. Konstantinides, MD, PhD, FESC Professor of Cardiology Democritus University of Thrace, Greece
More informationUnderstanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine
More informationBlood Day for Primary Care
Blood Day for Primary Care including the Anticoagulation, use of novel oral anticoagulants in DVT/PE & atrial fibrillation Marc Carrier MD MSc. FRCPC Department of Internal Medicine, Division of Hematology,
More informationDuration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016
Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be
More informationVenous Thromboembolic Disease Update
Canadian Society of Internal Medicine Annual Meeting Calgary, Alberta, October 2014 Venous Thromboembolic Disease Update Benjamin Bell, MD FRCPC James Douketis, MD FRCPC On Behalf of Thrombosis Canada
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationNew Guidance in AT10 Clive Kearon, MD, PhD,
New Guidance in AT10 Clive Kearon, MD, PhD, Professor, Department of Medicine, McMaster University; Program Director, McMaster Clinical Investigator Program, McMaster University Head, Clinical Thromboembolism
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationUpdates in Diagnosis & Management of VTE
Updates in Diagnosis & Management of VTE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE-SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationΑντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη
Αντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη Σταύρος Β. Κωνσταντινίδης, MD, PhD, FESC Καθηγητής Καρδιολογίας Δημοκρίτειο Πανεπιστήμιο Θράκης skonst@med.duth.gr Medical Director
More informationUnderstanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal
Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationManagement of Intermediate-Risk Pulmonary Embolism
Management of Intermediate-Risk Pulmonary Embolism Stavros V. Konstantinides, MD, PhD, FESC Professor, Clinical Trials in Antithrombotic Therapy Center for Thrombosis und Hemostasis, University of Mainz,
More informationAcute and long-term treatment of PE. Cecilia Becattini University of Perugia
Acute and long-term treatment of PE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE What is the optimal acute phase treatment for the patient? Intravenous thrombolysis One
More informationAnticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!)
Anticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!) Clinical Learning Day 2017 Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationA Patient with Chest Pain and Atrial Fibrillation
A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi
More informationUpdates in venous thromboembolism. Cecilia Becattini University of Perugia
Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15
More informationUpdates in Diagnosis & Management of VTE
Updates in Diagnosis & Management of VTE Financial Disclosures-NONE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE- SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA,
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationRapid Fire-Top Articles You Need to Know
Rapid Fire-Top Articles You Need to Know TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE- SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE
More informationChanging the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum
Online Data Supplement Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum Stacey M. Kassutto, C. Jessica Dine, Maryl Kreider, Rupal
More informationNew Developments in VTE Treatment
Disclosures: Accommodation at this meeting funded by Boehringer Investigator in phase III studies of Rivaroxiban, Dabigatran, Edoxaban New Developments in VTE Treatment GPCME meeting, August, Dunedin Dr
More informationAspirin as Venous Thromboprophylaxis
Canadian Society of Internal Medicine Nov 2, 2017 Aspirin as Venous Thromboprophylaxis Bill Geerts, MD, FRCPC Thromboembolism Consultant, Sunnybrook HSC Professor of Medicine, University of Toronto Disclosures
More informationThe latest on the diagnosis and treatment of venous thromboembolism
The latest on the diagnosis and treatment of venous thromboembolism Vicky Tagalakis MD FRCP Division of General Internal Medicine Jewish General Hospital McGill University Disclosures Advisory board Pfizer
More informationDOACs and CAT. 05 May 2017 NTW St Thomas Hospital
DOACs and CAT Alexander (Ander) Cohen Vascular Medicine / Haematology Guy s and St Thomas Hospitals, King s College, London 05 May 2017 NTW St Thomas Hospital Disclosures for Dr. Alexander (Ander) T. Cohen
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationAnticoagulation Update: DOACs, VTE Guidelines, Bridging and icentra
Anticoagulation Update: DOACs, VTE Guidelines, Bridging and icentra (whew!) Scott C. Woller, MD Co Director, Thrombosis Program Intermountain Medical Center Professor of Medicine University of Utah School
More informationABSTRACT INTRODUCTION
Adv Ther (2014) 31:473 493 DOI 10.1007/s12325-014-0119-7 REVIEW Phase III Trials of New Oral Anticoagulants in the Acute Treatment and Secondary Prevention of VTE: Comparison and Critique of Study Methodology
More informationThe Evidence Base for Treating Acute DVT
The Evidence Base for Treating Acute DVT Mr Chung Sim Lim Consultant Vascular Surgeon and Honorary Lecturer Royal Free London NHS Foundation Trust and University College London NIHR UCLH Biomedical Research
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC 1 st workshop: update to VTE guidelines in 2016 2 nd workshop: VTE controversies + new horizons André Roussin MD, FRCP, CSPQ CHUM
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationCancer Associated Thrombosis: six months and beyond. Farzana Haque Hull York Medical School
Cancer Associated Thrombosis: six months and beyond Farzana Haque Hull York Medical School Disclosure I have no disclosure The Challenge of Anticoagulation in Patients with Venous Thromboembolism and Cancer
More informationControversies in Venous Thromboembolism
Controversies in Venous Thromboembolism Menaka Pai, BSc MSc MD FRCPC Assistant Professor, Department of Medicine, McMaster University Associate Member, Department of Pathology and Molecular Medicine, McMaster
More informationThe spectrum of clinical outcome of PE
Practical treatment approach for patients with PE Cecilia Becattini University of Perugia The spectrum of clinical presentation of PE PE-related shock Mild clinical symptoms The spectrum of clinical outcome
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationNew Anticoagulants and Emerging Strategies
New Anticoagulants and Emerging Strategies in the Treatment of Venous Thromboembolism b Stavros V. Konstantinides, MD, PhD, FESC Head, Department of Cardiology, Democritus University of Thrace, Greece
More informationA BS TR AC T. BACKGROUND Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism.
The new england journal of medicine established in 82 august 29, 23 vol. 369 no. 9 Oral for the Treatment of Acute Venous Thromboembolism Giancarlo Agnelli, M.D., Harry R. Buller, M.D., Ph.D., Alexander
More informationNew areas of development for the direct oral anticoagulants
New areas of development for the direct oral anticoagulants Varese March 2016 Disclosures for Harry R Büller Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationThromboembolism and cancer: New practices. Marc Carrier
Thromboembolism and cancer: New practices Marc Carrier Marc Carrier Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board Leo Pharma, BMS No relevant
More informationEXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS
EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical
More informationTriple Therapy After PCI in AF: A Quagmire Soon to be Drained
Triple Therapy After PCI in AF: A Quagmire Soon to be Drained Freek W.A. Verheugt Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG) Amsterdam, Netherlands DISCLOSURES FOR FREEK W. A. VERHEUGT
More informationHow to prevent thrombotic diseases? Sergio Fusco, MD
How to prevent thrombotic diseases? Sergio Fusco, MD Geriatric Division - Department of Internal Medicine Ospedale Dell'Angelo - Venice, Italy CONFLICT OF INTEREST DISCLOSURE I have no potential conflict
More informationUC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
Updates in the Management of Venous Thromboembolism Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic Venous Thromboembolism
More informationNon commercial use only. The treatment of venous thromboembolism with new oral anticoagulants. Background
Italian Journal of Medicine 2013; volume 7(s8):29-35 The treatment of venous thromboembolism with new oral anticoagulants Davide Imberti AUSL Piacenza, Italy ABSTRACT Traditional anticoagulants, such as
More informationIs the combination of antithrombotics and lowdose anticoagulants worthwhile in PAD The VOYAGER trial
Is the combination of antithrombotics and lowdose anticoagulants worthwhile in PAD The VOYAGER trial Thomas HW Stadlbauer Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar, Technical
More informationAcute and long-term treatment of VTE. Cecilia Becattini University of Perugia
Acute and long-term treatment of VTE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE The goals The acute PE phase After the acute phase Treatment for VTE Goals of acute treatment
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationIS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?
IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS? J.Y. LE HEUZEY Georges Pompidou Hospital, René Descartes University, Paris H E G P Munich, August 27, 2012 Disclosure Consultant / Conferences / Advisory
More informationDOACs in SPECIAL POPULATIONS
DOACs in SPECIAL POPULATIONS Ann K Wittkowsky PharmD, CACP, FASHP, FCCP Clinical Professor University of Washington School of Pharmacy Director, Anticoagulation Services UWMedicine Department of Pharmacy
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationC. Michael Gibson, M.S., M.D. Professor of Medicine Harvard Medical School
Novel Strategies to Prevent Pulmonary Embolism and DVT: APEX Trial and Substudies C. Michael Gibson, M.S., M.D. Professor of Medicine Harvard Medical School Conflict of Interest Statement 2 Present Research/Grant
More informationNew Strategies and New Data- Beyond Guidelines
New Strategies and New Data- Beyond Guidelines Anthony Maraveyas GESCAT Lisbon 13 th October 2018 G.MA.GM.XA.12.2017.1962 Conflict of Interest Statement 2 u Research Support: Bayer, Boehringer Ingelheim,
More informationPulmonary embolism: Acute management. Cecilia Becattini University of Perugia, Italy
Pulmonary embolism: Acute management Cecilia Becattini University of Perugia, Italy Acute pulmonary embolism: Acute management Diagnosis Risk stratification Treatment Non-high risk PE: diagnosis 3-mo VTE
More informationDisclosures. Practical Considerations for Anticoagulation for Prevention of Venous Thromboembolism and Stroke Due to Atrial Fibrillation
12:45 1:45 pm Practical Considerations for Anticoagulation for Prevention of Venous Thromboembolism and Stroke Due to Atrial Fibrillation SPEAKER Christian Ruff, MD, MPH Presenter Disclosure Information
More informationClinical Cases with Deep Venous Thrombosis - The position of Apixaban Stavros KAKKOS, MD, MSc, PhD, RVT
Clinical Cases with Deep Venous Thrombosis - The position of Apixaban Stavros KAKKOS, MD, MSc, PhD, RVT Department of Vascular Surgery. University Hospital of Patras Chairman: Ioannis Tsolakis DISCLAIMER
More informationThe Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationMedical Patients: A Population at Risk
Case Vignette A 68-year-old woman with obesity was admitted to the Medical Service with COPD and pneumonia and was treated with oral corticosteroids, bronchodilators, and antibiotics. She responded well
More informationVenous thrombosis in unusual sites
Venous thrombosis in unusual sites Walter Ageno Department of Medicine and Surgery University of Insubria Varese Italy Disclosures Employment Research support Scientific advisory board Consultancy Speakers
More informationWhen and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD
When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven
More informationVTE: New Evidence, Best Practices, and Controversies
VTE: New Evidence, Best Practices, and Controversies Steven Deitelzweig, MD, MMM, SFHM Associate Professor of Medicine University of Queensland School of Medicine System Chairman Hospital Medicine Medical
More informationNew Perspective in VTE Treatment in Acute Medically Ill Patients: Single vs. Dual Drug Approach. Dr. Johan Kurnianda, SpPD-KHOM
New Perspective in VTE Treatment in Acute Medically Ill Patients: Single vs. Dual Drug Approach Dr. Johan Kurnianda, SpPD-KHOM VTE : Spectrum of Disease Deep Vein Thrombosis Post Thrombotic Syndrome Pulmonary
More informationImplications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach
Implications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach Prof. I. Baumgartner Head Clinical and Interventional Angiology About the ACCP guidelines Widely
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationA VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention
A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention This handout is a supplemental resource to an educational video activity released on Medscape
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More informationI nuovi anticoagulanti orali nella trombosi venosa profonda. Terapia della TVP. Fulvio POMERO. Medicina Interna S. Croce e Carle Cuneo
I nuovi anticoagulanti orali nella trombosi venosa profonda Terapia della TVP Fulvio POMERO Medicina Interna S. Croce e Carle Cuneo 1 2 3 Poor VKA control (first 90 days) Good VKA control (first 90 days)
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationWith All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis
BRIGHAM AND WOMEN S HOSPITAL With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis Gregory Piazza, MD, MS Division of Cardiovascular Medicine Brigham and Women s Hospital April
More informationReduced-dosed Rivaroxaban in the long-term prevention of recurrent symptomatic DVT The Einstein-Choice trial
Reduced-dosed Rivaroxaban in the long-term prevention of recurrent symptomatic DVT The Einstein-Choice trial Thomas HW Stadlbauer Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar,
More informationStatus of anticoagulation therapy in 2016: Is there a need for venous revascularization?
Status of anticoagulation therapy in 2016: Is there a need for venous revascularization? Rupert M. Bauersachs Dept. of Vascular Medicine, Darmstadt Center of Thrombosis Hemostasis, Mainz Status of anticoagulation
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationPlatelet inhibition PLUS low-dose anticoagulation a new paradigm for all PAD patients?
Platelet inhibition PLUS low-dose anticoagulation a new paradigm for all PAD patients? Thomas HW Stadlbauer, MD Klinikum rechts der Isar, Technical University of Munich Disclosure Speaker name: Thomas
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationDOACs in CAT. Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD
DOACs in CAT Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD Case 65 year old post menopausal female Left breast lesion Oct 2015 Biopsy Invasive ductal carcinoma Lumpectomy with SNB- pt1cno
More informationApixaban for Extended Treatment of Venous Thromboembolism
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Apixaban for Extended Treatment of Venous Thromboembolism Giancarlo Agnelli, M.D., Harry R. Buller, M.D., Ph.D., Alexander Cohen,
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationHow long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More information